Effect of interferon-α on hepatosplenomegaly and parasitemia
| . | Treatment* . | |||
|---|---|---|---|---|
| BSA . | IFN-α . | P yoelii + BSA . | P yoelii+ IFN-α . | |
| Liver weight, mg | 1010 ± 61 | 802 ± 50 | 1340 ± 25 | 1092 ± 25† |
| Spleen weight, mg | 93 ± 4 | 94 ± 11 | 686 ± 50 | 389 ± 16† |
| Parasitemia, % | — | — | 16.4 ± 9.8 | 0.8 ± 0.5† |
| . | Treatment* . | |||
|---|---|---|---|---|
| BSA . | IFN-α . | P yoelii + BSA . | P yoelii+ IFN-α . | |
| Liver weight, mg | 1010 ± 61 | 802 ± 50 | 1340 ± 25 | 1092 ± 25† |
| Spleen weight, mg | 93 ± 4 | 94 ± 11 | 686 ± 50 | 389 ± 16† |
| Parasitemia, % | — | — | 16.4 ± 9.8 | 0.8 ± 0.5† |
BSA indicates bovine serum albumin; IFN, interferon; P yoelii, Plasmodium yoelii.
Mice, infected or uninfected, were injected daily with 0.1% BSA or recombinant human IFN-α. Samples were taken 14 days afterP yoelii 265 BY inoculation. Results are mean ± SE of 4 mice per group. The experiment was repeated twice with similar results.
Significantly different (P < .05).P values were calculated by comparing IFN-α–treated infected mice with the corresponding infected control mice (Mann-Whitney test).